Comparison of eltrombopag and avatrombopag in the treatment of refractory/relapsed aplastic anemia: a single-center retrospective study in China

BACKGROUND: Eltrombopag (ELT), a thrombopoietin receptor agonist (TPO-RA), has been approved for relapsed/refractory aplastic anemia (AA). However, data on avatrombopag (AVA), another TPO-RA, are limited, and the comparisons between the two TPO-RAs are lacking. OBJECTIVES: We aimed to compare the ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Zhuxin, Hu, Qinglin, Yang, Chen, Chen, Miao, Han, Bing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503291/
https://www.ncbi.nlm.nih.gov/pubmed/37719987
http://dx.doi.org/10.1177/20406207231191310

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503291/
https://www.ncbi.nlm.nih.gov/pubmed/37719987
http://dx.doi.org/10.1177/20406207231191310

Ejemplares similares